Wall Street analysts expect that Solid Biosciences Inc (NASDAQ:SLDB) will post earnings per share of ($0.58) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Solid Biosciences’ earnings, with the highest EPS estimate coming in at ($0.55) and the lowest estimate coming in at ($0.60). Solid Biosciences posted earnings of ($0.84) per share in the same quarter last year, which suggests a positive year over year growth rate of 31%. The company is scheduled to issue its next earnings report on Thursday, April 4th.
According to Zacks, analysts expect that Solid Biosciences will report full year earnings of ($2.21) per share for the current financial year, with EPS estimates ranging from ($2.26) to ($2.17). For the next financial year, analysts anticipate that the company will post earnings of ($2.54) per share, with EPS estimates ranging from ($2.93) to ($2.22). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Solid Biosciences.
Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings data on Tuesday, November 13th. The company reported ($0.55) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.01.
A number of equities analysts have recently issued reports on SLDB shares. Zacks Investment Research raised Solid Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, August 16th. Credit Suisse Group started coverage on Solid Biosciences in a research note on Thursday, September 6th. They set a “neutral” rating and a $38.00 target price for the company. Finally, Citigroup started coverage on Solid Biosciences in a research note on Tuesday, November 6th. They set a “sell” rating and a $25.00 target price for the company. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. Solid Biosciences presently has a consensus rating of “Hold” and a consensus target price of $42.56.
Shares of SLDB stock traded down $1.86 during trading hours on Wednesday, reaching $28.49. 201,766 shares of the company’s stock were exchanged, compared to its average volume of 271,214. The company has a market cap of $1.10 billion and a price-to-earnings ratio of -9.89. Solid Biosciences has a 1 year low of $6.83 and a 1 year high of $54.84.
In other Solid Biosciences news, CEO Ilan Ganot sold 50,000 shares of the stock in a transaction on Thursday, November 15th. The stock was sold at an average price of $30.84, for a total transaction of $1,542,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Joel Solomon Zev Schneider sold 21,990 shares of the stock in a transaction on Thursday, November 15th. The shares were sold at an average price of $30.84, for a total value of $678,171.60. The disclosure for this sale can be found here. Insiders sold a total of 130,240 shares of company stock valued at $4,033,763 over the last ninety days.
A number of large investors have recently made changes to their positions in SLDB. Boxer Capital LLC grew its holdings in Solid Biosciences by 270.7% during the 2nd quarter. Boxer Capital LLC now owns 2,780,000 shares of the company’s stock valued at $99,051,000 after buying an additional 2,030,000 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in Solid Biosciences during the 3rd quarter valued at $24,288,000. Partner Fund Management L.P. acquired a new stake in Solid Biosciences during the 2nd quarter valued at $16,724,000. Vanguard Group Inc. grew its holdings in Solid Biosciences by 82.0% during the 3rd quarter. Vanguard Group Inc. now owns 675,180 shares of the company’s stock valued at $31,855,000 after buying an additional 304,286 shares during the last quarter. Finally, FMR LLC grew its holdings in Solid Biosciences by 424.4% during the 3rd quarter. FMR LLC now owns 317,997 shares of the company’s stock valued at $15,003,000 after buying an additional 257,354 shares during the last quarter. Hedge funds and other institutional investors own 63.59% of the company’s stock.
Solid Biosciences Company Profile
Solid Biosciences Inc engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation.
See Also: What is the quiet period?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.